Evaluation of cationic channel TRPV2 as a novel biomarker and therapeutic target in Leukemia-Implications concerning the resolution of pulmonary inflammation

Kodappully S. Siveen, Kirti S. Prabhu, Aeijaz S. Parray, Maysaloun Merhi, Abdelilah Arredouani, Mohamed Chikri, Shahab Uddin, Said Dermime, Ramzi M. Mohammad, Martin Steinhoff, Ibrahim A. Janahi, Fouad Azizi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Patients treated during leukemia face the risk of complications including pulmonary dysfunction that may result from infiltration of leukemic blast cells (LBCs) into lung parenchyma and interstitium. In LBCs, we demonstrated that transient receptor potential vanilloid type 2 channel (TRPV2), reputed for its role in inflammatory processes, exhibited oncogenic activity associated with alteration of its molecular expression profile. TRPV2 was overexpressed in LBCs compared to normal human peripheral blood mononuclear cells (PBMCs). Additionally, functional full length isoform and nonfunctional short form pore-less variant of TRPV2 protein were up-regulated and down-regulated respectively in LBCs. However, the opposite was found in PBMCs. TRPV2 silencing or pharmacological targeting by Tranilast (TL) or SKF96365 (SKF) triggered caspace-mediated apoptosis and cell cycle arrest. TL and SKF inhibited chemotactic peptide fMLP-induced response linked to TRPV2 Ca 2+ activity, and down-regulated expression of surface marker CD38 involved in leukemia and lung airway inflammation. Challenging lung airway epithelial cells (AECs) with LBCs decreased (by more than 50%) transepithelial resistance (TER) denoting barrier function alteration. Importantly, TL prevented such loss in TER. Therefore, TRPV2 merits further exploration as a pharmacodynamic biomarker for leukemia patients (with pulmonary inflammation) who might be suitable for a novel [adjuvant] therapeutic strategy based on TL.

Original languageEnglish
Article number1554
JournalScientific Reports
Volume9
Issue number1
DOIs
Publication statusPublished - 1 Dec 2019

Fingerprint

Transient Receptor Potential Channels
TRPV Cation Channels
Pneumonia
Leukemia
1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole
Biomarkers
Lung
Blood Cells
Therapeutics
Leukemic Infiltration
Cell Cycle Checkpoints
Protein Isoforms
Epithelial Cells
Pharmacology
Apoptosis
Peptides
tranilast
Proteins

ASJC Scopus subject areas

  • General

Cite this

Evaluation of cationic channel TRPV2 as a novel biomarker and therapeutic target in Leukemia-Implications concerning the resolution of pulmonary inflammation. / Siveen, Kodappully S.; Prabhu, Kirti S.; Parray, Aeijaz S.; Merhi, Maysaloun; Arredouani, Abdelilah; Chikri, Mohamed; Uddin, Shahab; Dermime, Said; Mohammad, Ramzi M.; Steinhoff, Martin; Janahi, Ibrahim A.; Azizi, Fouad.

In: Scientific Reports, Vol. 9, No. 1, 1554, 01.12.2019.

Research output: Contribution to journalArticle

Siveen, KS, Prabhu, KS, Parray, AS, Merhi, M, Arredouani, A, Chikri, M, Uddin, S, Dermime, S, Mohammad, RM, Steinhoff, M, Janahi, IA & Azizi, F 2019, 'Evaluation of cationic channel TRPV2 as a novel biomarker and therapeutic target in Leukemia-Implications concerning the resolution of pulmonary inflammation', Scientific Reports, vol. 9, no. 1, 1554. https://doi.org/10.1038/s41598-018-37469-8
Siveen, Kodappully S. ; Prabhu, Kirti S. ; Parray, Aeijaz S. ; Merhi, Maysaloun ; Arredouani, Abdelilah ; Chikri, Mohamed ; Uddin, Shahab ; Dermime, Said ; Mohammad, Ramzi M. ; Steinhoff, Martin ; Janahi, Ibrahim A. ; Azizi, Fouad. / Evaluation of cationic channel TRPV2 as a novel biomarker and therapeutic target in Leukemia-Implications concerning the resolution of pulmonary inflammation. In: Scientific Reports. 2019 ; Vol. 9, No. 1.
@article{41d2e921c30f442ea64a856df80a8fc9,
title = "Evaluation of cationic channel TRPV2 as a novel biomarker and therapeutic target in Leukemia-Implications concerning the resolution of pulmonary inflammation",
abstract = "Patients treated during leukemia face the risk of complications including pulmonary dysfunction that may result from infiltration of leukemic blast cells (LBCs) into lung parenchyma and interstitium. In LBCs, we demonstrated that transient receptor potential vanilloid type 2 channel (TRPV2), reputed for its role in inflammatory processes, exhibited oncogenic activity associated with alteration of its molecular expression profile. TRPV2 was overexpressed in LBCs compared to normal human peripheral blood mononuclear cells (PBMCs). Additionally, functional full length isoform and nonfunctional short form pore-less variant of TRPV2 protein were up-regulated and down-regulated respectively in LBCs. However, the opposite was found in PBMCs. TRPV2 silencing or pharmacological targeting by Tranilast (TL) or SKF96365 (SKF) triggered caspace-mediated apoptosis and cell cycle arrest. TL and SKF inhibited chemotactic peptide fMLP-induced response linked to TRPV2 Ca 2+ activity, and down-regulated expression of surface marker CD38 involved in leukemia and lung airway inflammation. Challenging lung airway epithelial cells (AECs) with LBCs decreased (by more than 50{\%}) transepithelial resistance (TER) denoting barrier function alteration. Importantly, TL prevented such loss in TER. Therefore, TRPV2 merits further exploration as a pharmacodynamic biomarker for leukemia patients (with pulmonary inflammation) who might be suitable for a novel [adjuvant] therapeutic strategy based on TL.",
author = "Siveen, {Kodappully S.} and Prabhu, {Kirti S.} and Parray, {Aeijaz S.} and Maysaloun Merhi and Abdelilah Arredouani and Mohamed Chikri and Shahab Uddin and Said Dermime and Mohammad, {Ramzi M.} and Martin Steinhoff and Janahi, {Ibrahim A.} and Fouad Azizi",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41598-018-37469-8",
language = "English",
volume = "9",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Evaluation of cationic channel TRPV2 as a novel biomarker and therapeutic target in Leukemia-Implications concerning the resolution of pulmonary inflammation

AU - Siveen, Kodappully S.

AU - Prabhu, Kirti S.

AU - Parray, Aeijaz S.

AU - Merhi, Maysaloun

AU - Arredouani, Abdelilah

AU - Chikri, Mohamed

AU - Uddin, Shahab

AU - Dermime, Said

AU - Mohammad, Ramzi M.

AU - Steinhoff, Martin

AU - Janahi, Ibrahim A.

AU - Azizi, Fouad

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Patients treated during leukemia face the risk of complications including pulmonary dysfunction that may result from infiltration of leukemic blast cells (LBCs) into lung parenchyma and interstitium. In LBCs, we demonstrated that transient receptor potential vanilloid type 2 channel (TRPV2), reputed for its role in inflammatory processes, exhibited oncogenic activity associated with alteration of its molecular expression profile. TRPV2 was overexpressed in LBCs compared to normal human peripheral blood mononuclear cells (PBMCs). Additionally, functional full length isoform and nonfunctional short form pore-less variant of TRPV2 protein were up-regulated and down-regulated respectively in LBCs. However, the opposite was found in PBMCs. TRPV2 silencing or pharmacological targeting by Tranilast (TL) or SKF96365 (SKF) triggered caspace-mediated apoptosis and cell cycle arrest. TL and SKF inhibited chemotactic peptide fMLP-induced response linked to TRPV2 Ca 2+ activity, and down-regulated expression of surface marker CD38 involved in leukemia and lung airway inflammation. Challenging lung airway epithelial cells (AECs) with LBCs decreased (by more than 50%) transepithelial resistance (TER) denoting barrier function alteration. Importantly, TL prevented such loss in TER. Therefore, TRPV2 merits further exploration as a pharmacodynamic biomarker for leukemia patients (with pulmonary inflammation) who might be suitable for a novel [adjuvant] therapeutic strategy based on TL.

AB - Patients treated during leukemia face the risk of complications including pulmonary dysfunction that may result from infiltration of leukemic blast cells (LBCs) into lung parenchyma and interstitium. In LBCs, we demonstrated that transient receptor potential vanilloid type 2 channel (TRPV2), reputed for its role in inflammatory processes, exhibited oncogenic activity associated with alteration of its molecular expression profile. TRPV2 was overexpressed in LBCs compared to normal human peripheral blood mononuclear cells (PBMCs). Additionally, functional full length isoform and nonfunctional short form pore-less variant of TRPV2 protein were up-regulated and down-regulated respectively in LBCs. However, the opposite was found in PBMCs. TRPV2 silencing or pharmacological targeting by Tranilast (TL) or SKF96365 (SKF) triggered caspace-mediated apoptosis and cell cycle arrest. TL and SKF inhibited chemotactic peptide fMLP-induced response linked to TRPV2 Ca 2+ activity, and down-regulated expression of surface marker CD38 involved in leukemia and lung airway inflammation. Challenging lung airway epithelial cells (AECs) with LBCs decreased (by more than 50%) transepithelial resistance (TER) denoting barrier function alteration. Importantly, TL prevented such loss in TER. Therefore, TRPV2 merits further exploration as a pharmacodynamic biomarker for leukemia patients (with pulmonary inflammation) who might be suitable for a novel [adjuvant] therapeutic strategy based on TL.

UR - http://www.scopus.com/inward/record.url?scp=85061283637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061283637&partnerID=8YFLogxK

U2 - 10.1038/s41598-018-37469-8

DO - 10.1038/s41598-018-37469-8

M3 - Article

C2 - 30733502

AN - SCOPUS:85061283637

VL - 9

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 1554

ER -